$NBIO has enrolled the first patient of the fifth
Post# of 144098
![Avatar](/images/ProfileImages/734810790_1098_wst.png)
![](/images/icons/icon_wink.gif)
Sean Carrick, Nascent CEO, explains, "We are enthusiastically encouraging anyone interested in screening for the trial to do so in a timely manner. This cohort of patients will likely be the final one in this trial, and new patient enrollment will cease until our Phase II research gets underway."
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)